KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”) OTCQB:PVCT, a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“R…
Peer-reviewed preclinical melanoma research finds Provectus’s synthetic small molecule can both stimulate anti-tumor immunity and suppress peripheral immune cells at the same dose.KNOXVILLE, Tenn., July 07, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) O…
Provectus converted accrued but unpaid directors' fees through June 30, 2026 into Series D-1 Preferred Stock, issuing 189,554 preferred shares (convertible into 1,895,540 common shares) to current board members.Original SEC Filing: PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ] - 8-K - Jun. 30, 2026Th…
KNOXVILLE, Tenn., June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) OTCQB:PVCT, a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, and…
